Saxagliptin (BMS-477118)
Catalog No. A11109
Saxagliptin (BMS-477118)是一种新型二肽基肽酶4(DPP-4)抑制剂,IC50为50 nM。
- OHE El-Shoubashy, .et al. Comparative study of HPLC-DAD and HPTLC for the simultaneous determination of a new multitarget antidiabetic ternary mixture in combined tablets, JPC, 2020, 33, 59-70
- Sato T, .et al. DPP8 is a novel therapeutic target for multiple myeloma, Sci Rep, 2019, Dec 2;9(1):18094 PMID: 31792328
- Chintan N. Koyani, .et al. Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes, Front Physiol, 2018, 9: 1622 PMID: 30487758
- Koyani CN, .et al. Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure, Biochem Pharmacol, 2016, Dec 1;145:64-80 PMID: 28859968
Catalog Num | A11109 |
---|---|
M. Wt | 315.4 |
Formula | C18H25N3O2 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 361442-04-8 |
Synonyms | BMS-477118,Onglyza |
SMILES | C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N |
Saxagliptin (BMS-477118)是一种新型二肽基肽酶4(DPP-4)抑制剂,IC50为50 nM。
Targets
DPP-4 | ||||
26 nM |
In vitro (25°C) | DMSO | 62 mg/mL (196.57 mM) | |
Water | 62 mg/mL (196.57 mM) | ||
Ethanol | 24 mg/mL (76.09 mM) | ||
In vivo | Saline | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 31.71 mL | 158.53 mL | 317.06 mL |
0.5 mM | 6.34 mL | 31.71 mL | 63.41 mL |
1 mM | 3.17 mL | 15.85 mL | 31.71 mL |
5 mM | 0.63 mL | 3.17 mL | 6.34 mL |
*The above data is based on the productmolecular weight 315.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.